LifeVantage Expands Global Reach with International Launch of the MB System™

Rhea-AI Summary

LifeVantage (LFVN) is expanding its MindBody GLP-1 System™ (MB System™) internationally following significant success in the U.S. market, where it contributed to a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024.

The MB System™ launched on March 15, 2025, in Japan for both Consultants and Customers, while becoming available exclusively to Consultants in Australia, New Zealand, Europe, UK, Mexico, and Thailand, with customer access starting April 25. The product is designed to naturally activate the body's GLP-1 production for metabolic health benefits.

The expansion targets the growing global GLP-1 pharmaceutical market, valued at $53.46 billion in 2024 and projected to reach $156.71 billion by 2030 with a 17.5% CAGR. LifeVantage plans to launch the MB System™ in the Philippines and Taiwan in early summer, followed by Canada later in the year.

Positive

• 49% year-over-year revenue increase in Q2 fiscal 2024
• Expansion into multiple international markets
• Clinical data confirms product effectiveness in supporting GLP-1 production
• Targeting rapidly growing GLP-1 market valued at $53.46B with 17.5% CAGR

Negative

• None.

Insights

Financial Analyst

LifeVantage's international expansion of its MB System™ represents a strategic growth initiative with substantial financial implications. The company's 49% year-over-year revenue increase in Q2 fiscal 2025 demonstrates the product's strong market traction in the US, providing a proven foundation for global expansion.

This international rollout strategically positions LifeVantage to capture market share in the rapidly growing GLP-1 sector, currently valued at $53.46 billion and projected to reach $156.71 billion by 2030 (growing at 17.5% CAGR). By leveraging its direct selling model, the company can potentially accelerate market penetration while controlling customer acquisition costs - an important advantage when entering multiple markets simultaneously.

The phased expansion approach is financially prudent, allowing LifeVantage to manage inventory, supply chain logistics, and training resources efficiently. Starting with Japan (a notoriously difficult but lucrative market to penetrate) demonstrates confidence, while the consultant-first strategy in other regions creates demand before full customer availability. This approach helps manage cash flow while building momentum.

With the MB System™ already proven as a revenue driver domestically, this expansion significantly increases LifeVantage's total addressable market, potentially transforming the company's revenue composition and geographic diversification - particularly valuable given the company's relatively modest $202 million market capitalization.

Healthcare Product Specialist

LifeVantage's MB System™ represents an innovative positioning in the metabolic health sector, offering consumers a natural alternative for activating endogenous GLP-1 production. While pharmaceutical GLP-1 receptor agonists have dominated headlines, this supplement-based approach targets consumers seeking non-prescription options for metabolic support.

The company's emphasis on clinical validation is particularly noteworthy. The article references clinical data supporting the formula's effectiveness in boosting natural GLP-1 production, suggesting LifeVantage has invested in substantiating product claims - critical for differentiation in the crowded supplement marketplace and for navigating varying international regulatory frameworks.

The MB System™ strategically aligns with the global shift toward holistic wellness approaches. By framing the product's benefits beyond weight management to include gut health, hormone function, and overall metabolic regulation, LifeVantage addresses diverse consumer health priorities across different cultural markets.

The timing is opportune as global awareness of GLP-1's multiple health benefits continues to rise. By launching in markets like Japan with strong traditional wellness philosophies, followed by regions with established supplement consumption patterns, LifeVantage has sequenced its expansion to maximize adoption potential. The product's positioning as a sustainable, long-term solution rather than a quick fix resonates with evolving consumer preferences for integrated health approaches rather than isolated interventions.

Following the highly successful launch in U.S. market, LifeVantage begins taking its groundbreaking MB System™ internationally

SALT LAKE CITY, March 17, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation^® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is extending its groundbreaking MindBody GLP-1 System™ to international markets. This expansion comes after a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024, in the U.S., largely driven by the system’s success, and clinical data on that formula reinforcing its effectiveness in supporting GLP-1 production.

The MB System™, as the product is known internationally, launched on March 15 for both LifeVantage Consultants and Customers in Japan. On the same date, it became available exclusively to Consultants in Australia, New Zealand, Europe, the UK, Mexico, and Thailand. Customers in these regions gain access starting April 25.

The MB System™ is designed to naturally activate the body's own GLP-1 production, providing a range of long-term health benefits that expand to weight management and beyond.*

“Consumers worldwide are seeking sustainable health solutions that go beyond short-term, unsustainable weight management,” said Steve Fife, President and CEO of LifeVantage. “The MB System™ works harmoniously with the body, empowering individuals to naturally enhance their metabolic health in alignment with their lifestyle and wellness objectives.”*

Meeting a Growing Global Demand
Interest in GLP-1 and metabolic health is rising worldwide. The global GLP-1 pharmaceutical market alone was valued at $53.46 billion in 2024 and is projected to grow at a CAGR of 17.5% from 2025 to 2030, reaching approximately $156.71 billion by 2030**.

In many regions, the focus is on holistic wellness, metabolic balance, and overall vitality in addition to weight management. The MB System™ aligns with this perspective by supporting the body's natural ability to regulate metabolism, gut health, and hormone function—key factors in long-term health.*

“The research that is emerging on all the positive health benefits of the GLP-1 hormone continues to excite us,” said Lisa Barnes, Vice President of Research & Development and Regulatory at LifeVantage. “From gut and digestive benefits, heart and cardiovascular benefits, and the health of other critical organs like the kidneys and liver, GLP-1 is a hormone essential for our longevity and vitality. We are so proud of this product and the clinically shown efficacy in activating the body’s own production of the hormone.”

Looking Ahead: Future Market Expansions
Early this summer, LifeVantage will launch the MB System™ in the Philippines and Taiwan, followed by Canada later in the year, completing the global rollout and reinforcing our commitment to providing natural Activation solutions worldwide.

For more information, visit LifeVantage.com.

About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
**https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market

Public Relations Contact:
Jennifer Rumble, CerconeBrownCompany
(704) 923-6378
lifevantage@cerconebrown.com

Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com

FAQ

What is the projected market size for GLP-1 products by 2030 according to LifeVantage (LFVN)?

The global GLP-1 pharmaceutical market is projected to reach $156.71 billion by 2030, growing at a CAGR of 17.5% from 2025.

How much did LifeVantage's (LFVN) revenue increase in Q2 2024 due to MB System?

LifeVantage reported a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024, largely driven by the MB System's success.

When will the MB System be available to customers in international markets like Australia and Europe?

Customers in Australia, New Zealand, Europe, UK, Mexico, and Thailand will gain access to the MB System starting April 25, 2025.

Which countries are included in LifeVantage's (LFVN) next phase of MB System expansion?

LifeVantage plans to launch the MB System in the Philippines and Taiwan in early summer, followed by Canada later in the year.